Vegetarians are healthier than meat-eaters: Study:- As per a recent study, the vegetarians are quite healthier than meat-eaters and it is applicable for adults of all the ages and their weights. This is also unaffected by alcohol consumption or smoking. Things are concluded as per the study conducted on 1,66,000 adults in the United Kingdom. It is presented at European Congress on Obesity (ECO) which is held online in 2021. The meat-eaters can have good and bad health effects as per their age and the chronic conditions. The metabolic benefits of the vegetarians is still unclear. The researchers of the University of Glasgow conducted a study and analyzed the data of 1,77,723 participants aged between 37 and 73 years in the UK Biobank.
13 maggio 2021 08:58
Fonte: Adnkronos
#chimica-e-farmacia
BAGSVÆRD, Denmark, May 13, 2021 /PRNewswire/ Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to significant improvements in physical functioning, such as climbing stairs and tying your shoes, and beneficial effects on weight related and health related quality of life scores (HRQoL) compared to placebo. Following the 68-week treatment period, more than half of participants had improved quality of life scores, indicating better physical function and improved psychological wellbeing.[1] The results from the STEP 1 trial will be presented today at the virtual European Congress on Obesity (ECO) 2021 Annual Meeting.
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } });
BAGSVÆRD, Denmark, May 13, 2021 /PRNewswire/ Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to significant improvements in physical functioning, such as climbing stairs and tying your shoes, and beneficial effects on weight related and health related quality of life scores (HRQoL) compared to placebo. Following the 68-week treatment period, more than half of participants had improved quality of life scores, indicating better physical function and improved psychological wellbeing.
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } });
BAGSVÆRD, Denmark, May 13, 2021 /PRNewswire/ Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to significant improvements in physical functioning, such as climbing stairs and tying your shoes, and beneficial effects on weight related and health related quality of life scores (HRQoL) compared to placebo. Following the 68-week treatment period, more than half of participants had improved quality of life scores, indicating better physical function and improved psychological wellbeing.
facebook
Pintrest
Ever since the start of the COVID pandemic, those with comorbidities including obesity, diabetes, hypertension are considered more at risk of getting a severe outcome of COVID infection. And if we go by the statistics, it’s clear that COVID infection turns suddenly severe and sometimes fatal in this group.
A new study has said that people with a higher body mass index (BMI) are at a higher risk of getting infected by the SARA-CoV 2 virus. Researchers from the Chaim Sheba Medical Center, Israel found people with higher body mass index have 22 per cent higher chances of testing positive as compared to people who have normal weight.